Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
29.1M
-
Number of holders
-
280
-
Total 13F shares, excl. options
-
28M
-
Shares change
-
+331K
-
Total reported value, excl. options
-
$4.94B
-
Value change
-
+$83.5M
-
Put/Call ratio
-
2.6
-
Number of buys
-
147
-
Number of sells
-
-119
-
Price
-
$176.53
Significant Holders of Krystal Biotech, Inc. - COMMON STOCK (KRYS) as of Q3 2025
329 filings reported holding KRYS - Krystal Biotech, Inc. - COMMON STOCK as of Q3 2025.
Krystal Biotech, Inc. - COMMON STOCK (KRYS) has 280 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 28M shares
of 29.1M outstanding shares and own 96.21% of the company stock.
Largest 10 shareholders include FMR LLC (4.34M shares), BlackRock, Inc. (3.83M shares), VANGUARD GROUP INC (2.79M shares), Avoro Capital Advisors LLC (2.78M shares), STATE STREET CORP (1.4M shares), Soleus Capital Management, L.P. (1.02M shares), Capital World Investors (809K shares), Frazier Life Sciences Management, L.P. (688K shares), Redmile Group, LLC (661K shares), and CITADEL ADVISORS LLC (637K shares).
This table shows the top 280 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.